Signaturefd LLC Sells 1,422 Shares of AstraZeneca plc (NYSE:AZN)
Signaturefd LLC cut its position in shares of AstraZeneca plc (NYSE:AZN) by 9.9% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,953 shares of the company’s stock after selling 1,422 shares during the period. Signaturefd LLC’s holdings in AstraZeneca were worth $535,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Manchester Financial Inc. bought a new position in shares of AstraZeneca in the 2nd quarter worth $25,000. Winslow Evans & Crocker Inc. raised its position in shares of AstraZeneca by 58.6% in the 2nd quarter. Winslow Evans & Crocker Inc. now owns 1,050 shares of the company’s stock worth $44,000 after acquiring an additional 388 shares in the last quarter. Heritage Wealth Advisors raised its position in shares of AstraZeneca by 3,378.1% in the 1st quarter. Heritage Wealth Advisors now owns 1,113 shares of the company’s stock worth $45,000 after acquiring an additional 1,081 shares in the last quarter. Legacy Advisors LLC bought a new position in shares of AstraZeneca in the 2nd quarter worth $48,000. Finally, Evolution Wealth Advisors LLC bought a new position in shares of AstraZeneca in the 2nd quarter worth $50,000. 18.42% of the stock is owned by institutional investors and hedge funds.
Several research analysts have recently commented on AZN shares. ValuEngine lowered AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research raised AstraZeneca from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a research report on Tuesday, April 16th. Finally, Pareto Securities raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, April 29th. Three analysts have rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $45.29.
AstraZeneca (NYSE:AZN) last announced its earnings results on Thursday, July 25th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.43. AstraZeneca had a return on equity of 37.25% and a net margin of 9.38%. The company had revenue of $5.72 billion for the quarter, compared to analyst estimates of $5.57 billion. During the same period in the prior year, the company posted $0.69 EPS. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. Analysts expect that AstraZeneca plc will post 1.79 earnings per share for the current year.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Quick Ratio
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.